...
首页> 外文期刊>Nefrologia >A comparison of cyclophosphamide versus tacrolimus in terms of treatment effect for idiopathic membranous nephropathy: A meta-analysis
【24h】

A comparison of cyclophosphamide versus tacrolimus in terms of treatment effect for idiopathic membranous nephropathy: A meta-analysis

机译:环磷酰胺与他克莫司治疗特发性膜性肾病的比较:一项荟萃分析

获取原文
           

摘要

Background and aimsIdiopathic membranous nephropathy (IMN), which is considered one of the most common causes of nephrotic syndrome in adult patients, is frequently managed with immunosuppressive agents. Both tacrolimus (TAC) and cyclophosphamide (CTX) are recommended as immunosuppressive agents in the management of IMN. However, profound effects and moderate evidence on the two drugs remains poorly defined at this period. The meta-analysis aims to summarize current best evidence on the efficacy as well as safety of TAC and CTX among IMN patients.MethodsWe searched the publications on comparison of the safety and efficacy of TAC versus CTX for IMN up to April 2018. After rigorous reviewing on the quality, the data was extracted from eligible trials. All trials analyzed the summary hazard ratios (HRs) of the endpoints of interest.ResultsModerate-strong evidence indicated that tacrolimus and cyclophosphamide had comparable effects on remission rate (either CR or PR) (p>0.05). No significant differences were found in the following parameters: the rates of diarrhea, glucose intolerance (or diabetes mellitus), gastrointestinal syndrome, as well as hypertension because of adverse effects (p>0.05). However, patients with TAC therapy had a higher chance to develop urinary tract infection (p=0.010) and tremor (p=0.006). Additionally, remarkably higher risk existed in leukopenia among the CTX group as compared with the TAC group (p=0.03).ConclusionThis meta-analysis presents a comprehensive assessment of current available evidence for the therapy of IMN, indicating a comparable remission rate with both TAC and CTX, while the long-term effects are needed for further verification. Nevertheless, different adverse effect profiles of two groups need careful consideration. Remarkably higher rates of urinary tract infection and tremor were observed among TAC group, while higher risk of leukopenia was found among CTX group. Further research into the treatment efficacy of both drugs is warranted to confirm the present conclusions.
机译:背景和目的特发性膜性肾病(IMN)被认为是成年患者肾病综合症的最常见原因之一,经常使用免疫抑制剂治疗。他克莫司(TAC)和环磷酰胺(CTX)均被推荐作为IMN管理中的免疫抑制剂。但是,在此期间,对这两种药物的深远影响和适度证据尚不清楚。荟萃分析旨在总结IMN患者中TAC和CTX的有效性和安全性的最佳证据。方法我们搜索了截至2018年4月的TAC和CTX对IMN的安全性和有效性比较的出版物。经过严格审查就质量而言,数据是从符合条件的试验中提取的。所有试验均分析了研究终点的总体危险比(HRs)。结果中度有力证据表明,他克莫司和环磷酰胺对缓解率(CR或PR)具有可比的影响(p> 0.05)。在以下参数中未发现显着差异:腹泻,葡萄糖耐受不良(或糖尿病),胃肠道综合症以及因不良反应引起的高血压的发生率(p> 0.05)。但是,接受TAC治疗的患者发生尿路感染(p = 0.010)和震颤(p = 0.006)的机会更高。此外,与TAC组相比,CTX组中白细胞减少症的风险显着更高(p = 0.03)。结论这项荟萃分析对IMN治疗的现有证据进行了全面评估,表明两种TAC的缓解率均相当。和CTX,而长期影响需要进一步验证。尽管如此,两组的不同不良反应情况仍需要仔细考虑。在TAC组中,尿路感染和震颤发生率显着较高,而在CTX组中,发现白细胞减少症的风险较高。有必要对这两种药物的治疗效果进行进一步研究以证实目前的结论。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号